Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › psilocybin

psilocybin

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of psilocybin

17 trials tracked of psilocybin.

17Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 14 Phase 1 3
  1. Phase 2 Psychopharmacology of Psilocybin in Cancer Patients Completed
  2. Phase 2 A Study of Psilocybin for Major Depressive Disorder (MDD) Completed
  3. Phase 2 Effects of Psilocybin in Major Depressive Disorder Completed
  4. Phase 2 The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression Completed
  5. Phase 2 The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression Completed
  6. Phase 2 Persisting Effects of Psilocybin Completed
Show 11 more trials
  1. Phase 2 A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence Completed
  2. Phase 2 Psilocybin-facilitated Treatment for Cocaine Use Completed
  3. Phase 2 Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer Completed
  4. Phase 2 Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia Completed
  5. Phase 2 The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder Completed
  6. Phase 2 Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder Completed
  7. Phase 2 Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence Completed
  8. Phase 2 Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care Completed
  9. Phase 1 Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors Completed
  10. Phase 1 Psilocybin Cancer Anxiety Study Completed
  11. Phase 1 Psilocybin-assisted CBT for Depression Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Psilocybin shows more robust evidence for sustained effects in treatment-resistant depression than ayahuasca
Psychiatry Sys. Review
Psilocybin shows more robust evidence for sustained effects in treatment-resistant depression than ayahuasca Psilocybin and Ayahuasca Show Potential for Treatment-Resistant Depression
This narrative review examines psilocybin and ayahuasca for treatment-resistant depression. The authors synthesize evidence showing rapid re…
New research highlights how psilocybin and ayahuasca may lead to rapid and sustained reductions in symptoms for people with treatment-resist…
Frontiers Sep 16, 2026
Microdosing psilocybin is associated with reported well-being and mental health benefits in some studies
Psychiatry Meta-analysis
Microdosing psilocybin is associated with reported well-being and mental health benefits in some studies Review of psilocybin microdosing for mental health and well-being
This systematic review of 3,262 participants examined the effects of microdosing psilocybin on mental health and substance use. While some s…
While some people report better mood and focus from psilocybin microdosing, the current evidence is limited by inconsistent methods.
Frontiers Aug 19, 2026
Three psilocybin doses (5–20 mg) in healthy volunteers showed dose-dependent functional connectivity changes.
Drug Pipeline RCT
Three psilocybin doses (5–20 mg) in healthy volunteers showed dose-dependent functional connectivity changes. Thinking Process:
This randomized controlled trial (RCT) enrolled 10 healthy volunteers who received three psilocybin doses between 5 and 20 mg in a randomize…
Lower psilocybin doses linked to decreased brain connectivity, while higher doses increased connections in healthy volunteers.
medRxiv Jun 4, 2026
Review of pooled psilocybin data suggests broadening blood pressure eligibility criteria for psychiatric trials
Psychiatry
Review of pooled psilocybin data suggests broadening blood pressure eligibility criteria for psychiatric trials Psilocybin raises blood pressure briefly but stays safe for most patients
This pooled analysis review examined blood pressure and heart rate responses in 368 participants receiving 536 psilocybin sessions at Johns …
New data shows psilocybin raises blood pressure only briefly, suggesting doctors could safely treat more patients with mild high blood press…
medRxiv Apr 30, 2026